FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000743316> ?p ?o ?g. }

• W2000743316 endingPage "294" @default.
• W2000743316 startingPage "287" @default.
• W2000743316 abstract "Wound healing in diabetic patients is slower than in healthy individuals. Erythropoietin (EPO) has non-hemopoietic targets in the skin, and systemically administered EPO promotes wound healing in experimental animals. This study investigated the effect of topical EPO treatment on defective wound repair in the skin of diabetic rats. Full-thickness excisional skin wounds were made in 38 rats, of which 30 had diabetes. The wounds were then treated topically with a cream that contained either vehicle, 600IUml−1 EPO (low dose), or 3,000IUml−1 (high dose) EPO. We assessed the rate of wound closure during the 12-day treatment period, and microvascular density (MVD), vascular endothelial growth factor (VEGF), and hydroxyproline (HP) contents, and the extent of apoptosis in wound tissues at the end of the 12-day treatment period. Topical EPO treatment significantly reduced the time to final wound closure. This increased rate of closure of the two EPO-treated wounds in diabetic rats was associated with increased MVD, VEGF, and HP contents, and a reduced extent of apoptosis. In light of our finding that topical EPO treatment promotes skin wound repair in diabetic rats, we propose that topical EPO treatment is a therapeutically beneficial method of treating chronic diabetic wounds. Wound healing in diabetic patients is slower than in healthy individuals. Erythropoietin (EPO) has non-hemopoietic targets in the skin, and systemically administered EPO promotes wound healing in experimental animals. This study investigated the effect of topical EPO treatment on defective wound repair in the skin of diabetic rats. Full-thickness excisional skin wounds were made in 38 rats, of which 30 had diabetes. The wounds were then treated topically with a cream that contained either vehicle, 600IUml−1 EPO (low dose), or 3,000IUml−1 (high dose) EPO. We assessed the rate of wound closure during the 12-day treatment period, and microvascular density (MVD), vascular endothelial growth factor (VEGF), and hydroxyproline (HP) contents, and the extent of apoptosis in wound tissues at the end of the 12-day treatment period. Topical EPO treatment significantly reduced the time to final wound closure. This increased rate of closure of the two EPO-treated wounds in diabetic rats was associated with increased MVD, VEGF, and HP contents, and a reduced extent of apoptosis. In light of our finding that topical EPO treatment promotes skin wound repair in diabetic rats, we propose that topical EPO treatment is a therapeutically beneficial method of treating chronic diabetic wounds. erythropoietin hydroxyproline microvascular density vascular endothelial growth factor" @default.
• W2000743316 created "2016-06-24" @default.
• W2000743316 creator A5026835359 @default.
• W2000743316 creator A5042879081 @default.
• W2000743316 creator A5051098181 @default.
• W2000743316 creator A5059063666 @default.
• W2000743316 creator A5063776146 @default.
• W2000743316 creator A5070038678 @default.
• W2000743316 date "2010-01-01" @default.
• W2000743316 modified "2023-10-16" @default.
• W2000743316 title "Topical Erythropoietin Promotes Wound Repair in Diabetic Rats" @default.
• W2000743316 cites W1882815675 @default.
• W2000743316 cites W1965150594 @default.
• W2000743316 cites W1969442477 @default.
• W2000743316 cites W1970325360 @default.
• W2000743316 cites W1971248512 @default.
• W2000743316 cites W1977879939 @default.
• W2000743316 cites W1979856207 @default.
• W2000743316 cites W1986945224 @default.
• W2000743316 cites W1993195370 @default.
• W2000743316 cites W2005495277 @default.
• W2000743316 cites W2006072798 @default.
• W2000743316 cites W2013735103 @default.
• W2000743316 cites W2017606827 @default.
• W2000743316 cites W2018688679 @default.
• W2000743316 cites W2024341333 @default.
• W2000743316 cites W2039211509 @default.
• W2000743316 cites W2043101178 @default.
• W2000743316 cites W2045677954 @default.
• W2000743316 cites W2055453684 @default.
• W2000743316 cites W2061426354 @default.
• W2000743316 cites W2073429818 @default.
• W2000743316 cites W2076261819 @default.
• W2000743316 cites W2081066824 @default.
• W2000743316 cites W2098923926 @default.
• W2000743316 cites W2101004964 @default.
• W2000743316 cites W2105362029 @default.
• W2000743316 cites W2106073768 @default.
• W2000743316 cites W2112937322 @default.
• W2000743316 cites W2121188367 @default.
• W2000743316 cites W2149541378 @default.
• W2000743316 cites W2151716122 @default.
• W2000743316 cites W2160549233 @default.
• W2000743316 cites W2315613377 @default.
• W2000743316 doi "https://doi.org/10.1038/jid.2009.219" @default.
• W2000743316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19626038" @default.
• W2000743316 hasPublicationYear "2010" @default.
• W2000743316 type Work @default.
• W2000743316 sameAs 2000743316 @default.
• W2000743316 citedByCount "81" @default.
• W2000743316 countsByYear W20007433162012 @default.
• W2000743316 countsByYear W20007433162013 @default.
• W2000743316 countsByYear W20007433162014 @default.
• W2000743316 countsByYear W20007433162015 @default.
• W2000743316 countsByYear W20007433162016 @default.
• W2000743316 countsByYear W20007433162017 @default.
• W2000743316 countsByYear W20007433162018 @default.
• W2000743316 countsByYear W20007433162019 @default.
• W2000743316 countsByYear W20007433162020 @default.
• W2000743316 countsByYear W20007433162021 @default.
• W2000743316 countsByYear W20007433162022 @default.
• W2000743316 countsByYear W20007433162023 @default.
• W2000743316 crossrefType "journal-article" @default.
• W2000743316 hasAuthorship W2000743316A5026835359 @default.
• W2000743316 hasAuthorship W2000743316A5042879081 @default.
• W2000743316 hasAuthorship W2000743316A5051098181 @default.
• W2000743316 hasAuthorship W2000743316A5059063666 @default.
• W2000743316 hasAuthorship W2000743316A5063776146 @default.
• W2000743316 hasAuthorship W2000743316A5070038678 @default.
• W2000743316 hasBestOaLocation W20007433161 @default.
• W2000743316 hasConcept C126322002 @default.
• W2000743316 hasConcept C134018914 @default.
• W2000743316 hasConcept C141071460 @default.
• W2000743316 hasConcept C167734588 @default.
• W2000743316 hasConcept C2777025900 @default.
• W2000743316 hasConcept C2778534260 @default.
• W2000743316 hasConcept C2779797417 @default.
• W2000743316 hasConcept C2780269544 @default.
• W2000743316 hasConcept C555293320 @default.
• W2000743316 hasConcept C71924100 @default.
• W2000743316 hasConceptScore W2000743316C126322002 @default.
• W2000743316 hasConceptScore W2000743316C134018914 @default.
• W2000743316 hasConceptScore W2000743316C141071460 @default.
• W2000743316 hasConceptScore W2000743316C167734588 @default.
• W2000743316 hasConceptScore W2000743316C2777025900 @default.
• W2000743316 hasConceptScore W2000743316C2778534260 @default.
• W2000743316 hasConceptScore W2000743316C2779797417 @default.
• W2000743316 hasConceptScore W2000743316C2780269544 @default.
• W2000743316 hasConceptScore W2000743316C555293320 @default.
• W2000743316 hasConceptScore W2000743316C71924100 @default.
• W2000743316 hasIssue "1" @default.
• W2000743316 hasLocation W20007433161 @default.
• W2000743316 hasLocation W20007433162 @default.
• W2000743316 hasOpenAccess W2000743316 @default.
• W2000743316 hasPrimaryLocation W20007433161 @default.
• W2000743316 hasRelatedWork W1533499877 @default.
• W2000743316 hasRelatedWork W180630451 @default.
• W2000743316 hasRelatedWork W1970708287 @default.

• next